{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:07:00Z","timestamp":1790838420791,"version":"4.1.0"},"reference-count":39,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2018,1,15]],"date-time":"2018-01-15T00:00:00Z","timestamp":1515974400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"},{"start":{"date-parts":[[2018,1,15]],"date-time":"2018-01-15T00:00:00Z","timestamp":1515974400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"LEO Pharma A\/S"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Dermatol"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1111\/bjd.16048","type":"journal-article","created":{"date-parts":[[2017,10,14]],"date-time":"2017-10-14T04:36:33Z","timestamp":1507955793000},"page":"433-442","source":"Crossref","is-referenced-by-count":25,"title":["Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0\u00b7015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp"],"prefix":"10.1093","volume":"178","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1922-9062","authenticated-orcid":false,"given":"E.","family":"Stockfleth","sequence":"first","affiliation":[{"name":"Klinik f\u00fcr Dermatologie; Venerologie und Allergologie; St. Josef-Hospital; Bochum Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1375-0965","authenticated-orcid":false,"given":"C.A.","family":"Harwood","sequence":"additional","affiliation":[{"name":"Centre for Cell Biology and Cutaneous Research; Blizard Institute; Barts and the London School of Medicine and Dentistry; Queen Mary University of London; London U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Serra-Guill\u00e9n","sequence":"additional","affiliation":[{"name":"Department of Dermatology; Instituto Valenciano de Oncolog\u00eda; Valencia Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Larsson","sequence":"additional","affiliation":[{"name":"LEO Pharma A\/S; Ballerup Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.L.","family":"\u00d8sterdal","sequence":"additional","affiliation":[{"name":"LEO Pharma A\/S; Ballerup Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Skov","sequence":"additional","affiliation":[{"name":"LEO Pharma A\/S; Ballerup Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,1,15]]},"reference":[{"key":"10.1111\/bjd.16048-BIB0001|bjd16048-cit-0001","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1016\/j.jaad.2012.09.053","article-title":"Pathobiology of actinic keratosis: ultraviolet-dependent keratinocyte proliferation","volume":"68","author":"Berman","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.16048-BIB0002|bjd16048-cit-0002","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.jaad.2012.10.001","article-title":"The importance of early diagnosis and treatment of actinic keratosis","volume":"68","author":"Rigel","year":"2013","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.16048-BIB0003|bjd16048-cit-0003","first-page":"1727","article-title":"A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications","volume":"63","author":"Braakhuis","year":"2003","journal-title":"Cancer Res"},{"key":"10.1111\/bjd.16048-BIB0004|bjd16048-cit-0004","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1067\/mjd.2000.103339","article-title":"The risk of progression to invasive disease","volume":"42","author":"Glogau","year":"2000","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.16048-BIB0005|bjd16048-cit-0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/jdv.12833","article-title":"A new vision of actinic keratosis beyond visible clinical lesions","volume":"29","author":"Malvehy","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.16048-BIB0006|bjd16048-cit-0006","doi-asserted-by":"crossref","first-page":"2523","DOI":"10.1002\/cncr.24284","article-title":"Actinic keratoses: natural history and risk of malignant transformation in the veterans affairs topical tretinoin chemoprevention trial","volume":"115","author":"Criscione","year":"2009","journal-title":"Cancer"},{"key":"10.1111\/bjd.16048-BIB0007|bjd16048-cit-0007","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1111\/bjd.12420","article-title":"The natural history of actinic keratosis: a systematic review","volume":"169","author":"Werner","year":"2013","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.16048-BIB0008|bjd16048-cit-0008","unstructured":"Werner RN Stockfleth E Connolly SM et\u00a0al Evidence and consensus based (S3) guidelines for the treatment of actinic keratosis http:\/\/www.euroderm.org\/edf\/index.php\/edf-guidelines\/category\/5-guidelines-miscellaneous?download=23:guideline-management-of-actinic-keratoses-update-2015"},{"key":"10.1111\/bjd.16048-BIB0009|bjd16048-cit-0009","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1111\/jdv.12848","article-title":"Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin","volume":"29","author":"Fernandez-Figueras","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.16048-BIB0010|bjd16048-cit-0010","doi-asserted-by":"crossref","first-page":"33952","DOI":"10.1038\/srep33952","article-title":"Thickness of actinic keratosis does not predict dysplasia severity or P53 expression","volume":"6","author":"Heerfordt","year":"2016","journal-title":"Sci Rep"},{"key":"10.1111\/bjd.16048-BIB0011|bjd16048-cit-0011","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1046\/j.1523-1747.2000.00048.x","article-title":"High incidence and regression rates of solar keratoses in a Queensland community","volume":"115","author":"Frost","year":"2000","journal-title":"J Invest Dermatol"},{"key":"10.1111\/bjd.16048-BIB0012|bjd16048-cit-0012","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/bjd.14222","article-title":"Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0.015% gel: a randomized, controlled 12-month study","volume":"174","author":"Garbe","year":"2016","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.16048-BIB0013|bjd16048-cit-0013","first-page":"741","article-title":"Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12-month results","volume":"13","author":"Berman","year":"2014","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/bjd.16048-BIB0014|bjd16048-cit-0014","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1080\/09546634.2016.1178372","article-title":"Adherence to topical therapies in actinic keratosis: a literature review","volume":"27","author":"Foley","year":"2016","journal-title":"J Dermatolog Treat"},{"key":"10.1111\/bjd.16048-BIB0015|bjd16048-cit-0015","first-page":"1181","article-title":"Biological effects of ingenol mebutate gel in moderate to severe actinic fields assessed by reflectance confocal microscopy: a phase I study","volume":"15","author":"Ulrich","year":"2016","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/bjd.16048-BIB0016|bjd16048-cit-0016","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/jdv.13648","article-title":"Italian expert consensus for the management of actinic keratosis in immunocompetent patients","volume":"30","author":"Peris","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"10.1111\/bjd.16048-BIB0017|bjd16048-cit-0017","unstructured":"Pharmaderm Solaraze \u00ae gel. Prescribing information http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2011\/021005s013lbl.pdf"},{"key":"10.1111\/bjd.16048-BIB0018|bjd16048-cit-0018","first-page":"1011","article-title":"Modes of action of diclofenac 3%\/hyaluronic acid 2.5% in the treatment of actinic keratosis","volume":"9","author":"Maltusch","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"key":"10.1111\/bjd.16048-BIB0019|bjd16048-cit-0019","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2147\/TCRM.S12498","article-title":"Diclofenac gel in the treatment of actinic keratoses","volume":"7","author":"Nelson","year":"2011","journal-title":"Ther Clin Risk Manag"},{"key":"10.1111\/bjd.16048-BIB0020|bjd16048-cit-0020","first-page":"35","article-title":"Non-adherence to topical treatments for actinic keratosis","volume":"8","author":"Shergill","year":"2013","journal-title":"Patient Prefer Adherence"},{"key":"10.1111\/bjd.16048-BIB0021|bjd16048-cit-0021","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1111\/ijd.12840","article-title":"A consensus approach to improving patient adherence and persistence with topical treatment for actinic keratosis","volume":"54","author":"Stockfleth","year":"2015","journal-title":"Int J Dermatol"},{"key":"10.1111\/bjd.16048-BIB0022|bjd16048-cit-0022","unstructured":"LEO Pharma Picato \u00ae prescribing information http:\/\/www.leo-pharma.us\/Files\/Billeder\/LEO_local_images\/LEO-Pharma.US\/Releases\/Picato%20PI.pdf"},{"key":"10.1111\/bjd.16048-BIB0023|bjd16048-cit-0023","doi-asserted-by":"crossref","first-page":"111","DOI":"10.2147\/CCID.S28905","article-title":"New developments in the treatment of actinic keratosis: focus on ingenol mebutate gel","volume":"5","author":"Berman","year":"2012","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"10.1111\/bjd.16048-BIB0024|bjd16048-cit-0024","doi-asserted-by":"crossref","first-page":"e0160096","DOI":"10.1371\/journal.pone.0160096","article-title":"Tumor-preferential induction of immune responses and epidermal cell death in actinic keratoses by ingenol mebutate","volume":"11","author":"Emmert","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1111\/bjd.16048-BIB0025|bjd16048-cit-0025","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJMoa1111170","article-title":"Ingenol mebutate gel for actinic keratosis","volume":"366","author":"Lebwohl","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1111\/bjd.16048-BIB0026|bjd16048-cit-0026","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1477-7525-2-12","article-title":"Validation of a general measure of treatment satisfaction, the Treatment Satisfaction Questionnaire for Medication (TSQM), using a national panel study of chronic disease","volume":"2","author":"Atkinson","year":"2004","journal-title":"Health Qual Life Outcomes"},{"key":"10.1111\/bjd.16048-BIB0027|bjd16048-cit-0027","first-page":"401","article-title":"Phase IV, open-label assessment of the treatment of actinic keratosis with 3.0% diclofenac sodium topical gel (Solaraze)","volume":"3","author":"Nelson","year":"2004","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/bjd.16048-BIB0028|bjd16048-cit-0028","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1046\/j.1365-2133.2002.04561.x","article-title":"Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel","volume":"146","author":"Rivers","year":"2002","journal-title":"Br J Dermatol"},{"key":"10.1111\/bjd.16048-BIB0029|bjd16048-cit-0029","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1046\/j.1365-4362.2001.01324.x","article-title":"Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses","volume":"40","author":"Wolf","year":"2001","journal-title":"Int J Dermatol"},{"key":"10.1111\/bjd.16048-BIB0030|bjd16048-cit-0030","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1177\/0394632017697719","article-title":"Pharmacoeconomic evaluations in the treatment of actinic keratoses","volume":"30","author":"Tolley","year":"2017","journal-title":"Int J Immunopath PH"},{"key":"10.1111\/bjd.16048-BIB0031|bjd16048-cit-0031","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1046\/j.1440-0960.2002.00635.x","article-title":"Topical diclofenac in hyaluronan gel for the treatment of solar keratoses","volume":"44","author":"Gebauer","year":"2003","journal-title":"Australas J Dermatol"},{"key":"10.1111\/bjd.16048-BIB0032|bjd16048-cit-0032","doi-asserted-by":"crossref","first-page":"e96829","DOI":"10.1371\/journal.pone.0096829","article-title":"A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe","volume":"9","author":"Vegter","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1111\/bjd.16048-BIB0033|bjd16048-cit-0033","doi-asserted-by":"crossref","first-page":"450","DOI":"10.3109\/09546634.2016.1160024","article-title":"Quality of life in treatment of AK: treatment burden of ingenol mebutate gel is small and short lasting","volume":"27","author":"Hanke","year":"2016","journal-title":"J Dermatolog Treat"},{"key":"10.1111\/bjd.16048-BIB0034|bjd16048-cit-0034","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1111\/j.1365-4632.2012.05776.x","article-title":"Understanding efficacy end-points in studies of field-directed therapy for actinic keratosis","volume":"52","author":"Wolf","year":"2013","journal-title":"Int J Dermatol"},{"key":"10.1111\/bjd.16048-BIB0035|bjd16048-cit-0035","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.jaad.2015.01.036","article-title":"Ingenol mebutate gel for actinic keratosis: the link between quality of life, treatment satisfaction, and clinical outcomes","volume":"72","author":"Augustin","year":"2015","journal-title":"J Am Acad Dermatol"},{"key":"10.1111\/bjd.16048-BIB0036|bjd16048-cit-0036","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1158\/1535-7163.MCT-15-0023-T","article-title":"Ingenol mebutate signals via PKC\/MEK\/ERK in keratinocytes and induces interleukin decoy receptors IL1R2 and IL13RA2","volume":"14","author":"Freiberger","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"10.1111\/bjd.16048-BIB0037|bjd16048-cit-0037","first-page":"1181","article-title":"Ingenol mebutate: induced cell death patterns in normal and cancer epithelial cells","volume":"11","author":"Stahlhut","year":"2012","journal-title":"J Drugs Dermatol"},{"key":"10.1111\/bjd.16048-BIB0038|bjd16048-cit-0038","first-page":"1339","article-title":"Biologic effects of light: an enlighting prospective","volume":"36","author":"Reichrath","year":"2016","journal-title":"Anticancer Res"},{"key":"10.1111\/bjd.16048-BIB0039|bjd16048-cit-0039","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1468-3083.2011.04005.x","article-title":"Open label randomized study comparing 3\u00a0months vs. 6\u00a0months treatment of actinic keratoses with 3% diclofenac in 2.5% hyaluronic acid gel: a trial of the German Dermatologic Cooperative Oncology Group","volume":"26","author":"Pflugfelder","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.16048","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/bjd.16048\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,14]],"date-time":"2023-02-14T09:30:13Z","timestamp":1676367013000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/178\/2\/433\/6732196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,15]]},"references-count":39,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,2]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.16048","archive":["Portico"],"relation":{},"ISSN":["0007-0963"],"issn-type":[{"value":"0007-0963","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1,15]]}}}